POM121 transmembrane nucleoporin B (pseudogene)Genealiases: []
Q-omics provides the consensus-scored POM121B profile across patient tissues and cancer cell-line models. POM121B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, POM121B is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, POM121B RNA expression shows 15,621 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight STAD, HNSC, and DLBC as cancer lineages where POM121B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POM121B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POM121B survival associations across molecular data types. POM121B RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POM121B RNA expression–survival associations across cancer types. High POM121B expression shows unfavorable associations in STAD, UVM and CESC, but favorable associations in BRCA, LAML and MESO. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify STAD as the clearest survival context for POM121B RNA expression.
This table summarizes POM121B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for POM121B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POM121B shows higher tumor expression in HNSC, COAD, STAD, LUSC, LIHC and KIRC. The HNSC box plot shows higher POM121B RNA expression in tumor versus normal tissue (log2 FC = +0.330, t-test p < 0.001).
This table shows molecular features associated with POM121B in patient tissues and cancer cell lines. In patient samples, POM121B shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
